Grants per year
Personal profile
Research Interests
Personalized Cancer Therapy, Precision Medicine, Early Phase Clinical Trials, First-in-Human Study, Novel Combination Cancer Therapy, Targeted therapy, Immunotherapy, Biomarker Study, Novel Drug Development, Novel Drug Delivery System, Adaptive Clinical Trials Design, Cell Signaling Pathway, Immune Checkpoint Pathway
Training Experience
| 2011 | Residency, Albert Einstein Medical Center |
| 2014 | Fellowship, University of Texas/MD Anderson Cancer Center |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MBA, Medical Management, Johns Hopkins University
… → 2007
MPH, Public Health, Johns Hopkins University
… → 2007
MD, Medicine, Seoul National University
… → 2002
Research interests keywords
- Oncology
Fingerprint
Dive into the research topics where Young Kwang Chae is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #NU17Z01: Blood Biomarker Analysis in Patients with Solid Tumors or Lymphoma
Chae, Y. K. (PD/PI)
3/4/25 → 3/4/28
Project: Research project
-
Prot #TV56278-ONC-10203: A Phase 1a/1b Open-Label, Multicenter, Dose Escalation, and Dose Expansion Trial to Evaluate the Safety and Activity of TEV-56278, as a Monotherapy and in Combination with Pembrolizumab in Participants with Selected Locally Advanc
Chae, Y. K. (PD/PI)
ICON Clinical Research, LLC, Teva Branded Pharmaceutical Products R&D, Inc.
11/13/24 → 11/13/27
Project: Research project
-
Prot #1454‐0001: A First‐in‐Human Phase I, Non‐Randomized, Open‐Label, Multicenter Dose Escalation Trial of BI 765049 and BI 765049 + Ezabenlimab (BI 754091) Administered by Repeated Intravenous Infusions in Patients with Malignant Solid Tumors Expressi
Chae, Y. K. (PD/PI)
SCRI Development Innovations, LLC, Boehringer Ingelheim Pharmaceuticals, Inc.
11/10/23 → 11/10/26
Project: Research project
-
A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial)
Le, X., Patel, J. D., Shum, E., Baik, C., Sanborn, R. E., Shu, C. A., Kim, C., Fidler, M. J., Hall, R., Elamin, Y. Y., Tu, J., Blumenschein, G., Zhang, J., Gibbons, D., Gay, C., Mohindra, N. A., Chae, Y., Boumber, Y., Sabari, J. & Santana-Davila, R. & 10 others, , Feb 1 2025, In: Journal of Clinical Oncology. 43, 4, p. 403-411 9 p.Research output: Contribution to journal › Article › peer-review
16 Scopus citations -
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors SWOG S1609: Vulvar Cancers
Chae, Y. K., Corthell, L., Patel, S. P., Edwards, R., Scalici, J. M., Kim, H. S., Chung, L. I. Y., Othus, M., McLeod, C. M., Chen, H. X., Sharon, E., Streicher, H., Ryan, C. W., Blanke, C. D. & Kurzrock, R., Jan 15 2025, In: Clinical Cancer Research. 31, 2, p. 308-315 8 p.Research output: Contribution to journal › Article › peer-review
-
Delta Radiomics and Tumor Size: A New Predictive Radiomics Model for Chemotherapy Response in Liver Metastases from Breast and Colorectal Cancer
Gennaro, N., Soliman, M., Borhani, A. A., Kelahan, L., Savas, H., Avery, R. J., Subedi, K., Trabzonlu, T. A., Krumpelman, C., Yaghmai, V., Chae, Y. K., Lorch, J., Mahalingam, D., Mulcahy, M., Benson III, A. B., Bagci, U. & Velichko, Y. S., Mar 2025, In: Tomography. 11, 3, 20.Research output: Contribution to journal › Article › peer-review
Open Access -
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinoma
Patel, S. P., Cano-Linson, E., Chae, Y. K., Schokrpur, S., Lao, C. D., Powers, B. C., Victor, A. I., Onitilo, A. A., Shin, S., Takebe, N., Threlkel, S., McLeod, C. M., Chen, H. X., Sharon, E., Othus, M., Ryan, C. W., Blanke, C. D. & Kurzrock, R., Dec 2025, In: npj Precision Oncology. 9, 1, 24.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
First cycle toxicity and survival in patients with rare cancers treated with checkpoint inhibitors
Othus, M., Patel, S. P., Chae, Y. K., Dietrich, E., Streicher, H., Sharon, E. & Kurzrock, R., Apr 1 2025, In: Journal of the National Cancer Institute. 117, 4, p. 692-700 9 p.Research output: Contribution to journal › Article › peer-review
Open Access
Datasets
-
Exceptional response to chemotherapy followed by concurrent radiotherapy and immunotherapy in a male with primary retroperitoneal serous Adenocarcinoma: a case report and literature review
Chae, Y. K. (Creator), Saleem, N. (Creator), Roh, Y. (Contributor), Bilal, H. (Creator), Viveiros, P. (Creator), Sukhadia, B. (Contributor), Lin, X. (Contributor), Sheikh, M. M. (Creator) & Park, L. C. (Creator), figshare, 2019
DOI: 10.6084/m9.figshare.c.4601576, https://springernature.figshare.com/collections/Exceptional_response_to_chemotherapy_followed_by_concurrent_radiotherapy_and_immunotherapy_in_a_male_with_primary_retroperitoneal_serous_Adenocarcinoma_a_case_report_and_literature_review/4601576
Dataset
-
Supplementary Material for: Cushing’s Syndrome in Adenocarcinoma of Lung Responding to Osilodrostat
Heleno, C. T. (Contributor), Hong, S. P. D. (Contributor), Cho, H.-G. (Contributor), Kim, M. J. (Contributor), Park, Y. (Contributor) & Chae, Y. K. (Contributor), Karger Publishers, 2023
DOI: 10.6084/m9.figshare.22146836.v1, https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Cushing_s_Syndrome_in_Adenocarcinoma_of_Lung_Responding_to_Osilodrostat/22146836/1
Dataset